<DOC>
	<DOCNO>NCT02694874</DOCNO>
	<brief_summary>Even optimal anti-malaria therapy supportive care , severe cerebral malaria associate 10-30 % mortality rate neurocognitive deficit 33 % survivor . Adjunctive therapy modify host immune-pathological process may improve outcome possible anti-malarials alone . Investigators aim evaluate PPARγ agonist ( `` rosiglitazone '' ) adjunctive therapy severe malaria .</brief_summary>
	<brief_title>Rosiglitazone Adjunctive Therapy Severe Malaria Children</brief_title>
	<detailed_description>Although use artemisinin-based therapy improve outcome severe malaria , mortality rate remain high . Adjunctive therapy target underlying immunopathology may reduce morbidity mortality severe cerebral malaria beyond possible anti-malarials alone . Pre-clinical data establish beneficial role PPARγ agonists experimental cerebral malaria . A proof-of-concept randomized clinical trial uncomplicated malaria Thailand extend finding informative patient population , show adjunctive treatment PPARγ agonist rosiglitazone improve parasite clearance , reduce biomarkers inflammation ( IL-6 MCP-1 ) endothelial activation ( Ang-2 Ang-1 ratio ) , increase neuro-protective pathway ( BDNF ) . The previous clinical trial also establish safety tolerability short course rosiglitazone adult malaria infection . Importantly , rosiglitazone induce insulin release hypoglycemia malaria-infected patient . Based data , study demonstrate neuro-protective effect PPARγ agonists CNS disease injury , investigator believe PPARγ agonist promise candidate adjunctive therapy severe cerebral malaria . In study efficacy rosiglitazone vs. placebo control adjunct standard care anti-malarial therapy child severe ( include cerebral ) malaria test . The underlying hypothesis addition rosiglitazone standard antimalarial therapy severe P. falciparum infection safe result improve clinical outcome low rate long-term neurocognitive impairment .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Age 112 year Positive 3band ( HRPII plus pLDH ) P. falciparum rapid diagnostic test ( RDT ) microscopy confirm malaria infection parasitemia &gt; 2500 parasites/microlitre microscopy available timely manner time randomization . One feature severe malaria : repeat seizure ( two generalize seizure 24 h ) ; prostration ( child 1 year older , child unable sit unsupported stand although able illness ) ; impair consciousness ( Blantyre Coma Score &lt; 5 child 1 4 year , GCS &lt; 14 child ≥ 5 year ) ; respiratory distress : age related tachypnea sustain nasal flaring , deep breathing subcostal retraction Requiring hospitalization parenteral artesunate malaria infection base admit physician assessment P. falciparum RDT negative OR infection confirm light microscopy reach predefined inclusion criterion parasitemia threshold accord age Uncomplicated malaria infection require hospitalization Presenting severe malaria anemia ( SMA ) alone ( Hb &lt; 50g/L ) Known underlying illness : neurological neurodegenerative disorder , cardiac , renal , hepatic disease , diabetes , epilepsy , cerebral palsy , child know HIV1 positive receive antiretroviral treatment* Previous treatment TZD Unable remain research site region follow period</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adjunctive treatment</keyword>
	<keyword>Severe malaria</keyword>
</DOC>